Nina Woodworth, Chief Business Officer at Redoxis, will attend Nordic Life Science Days in Stockholm on 8 September 2026.
Redoxis supports biotech and pharmaceutical companies with tailored preclinical studies in inflammation, autoimmunity and neuroinflammation. By combining in vivo and in vitro models with high-resolution biology, we help project teams generate robust efficacy data and deeper mechanistic insight.
Meet Nina to discuss:
- Selecting a relevant preclinical model for your therapeutic candidate
- Designing integrated in vivo, in vitro and ex vivo study programmes
- Combining efficacy studies with histology, imaging and biomarker analysis
- Developing or adapting models and methods for specific mechanisms of action
- Translating early scientific questions into clear, decision-enabling study plans
If you are developing a therapeutic programme in inflammation or autoimmune disease, we would be pleased to discuss how Redoxis can support your next preclinical decision.
Book a meeting with Nina at Nordic Life Science Days.